The Effect of MK0633 in Patients With Chronic Asthma (0633-007)
Phase 2
Terminated
- Conditions
- Asthma
- Interventions
- Drug: MK0633
- Registration Number
- NCT00404313
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
A clinical study to evaluate the efficacy and safety of MK0633 in adult patients with chronic asthma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 688
Inclusion Criteria
- Documented clinical history of symptoms of chronic asthma, including dyspnea, wheezing, chest tightness, cough, and/or sputum production
- Males and females 18-70 years of age
Read More
Exclusion Criteria
- History of kidney or chronic liver disease
- Recent history of heart problems within the past 3 months
- Evidence of another clinically significant, active lung disorder such as bronchiectasis or COPD
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 MK0633 MK0633 50 mg 1 MK0633 MK0633 10 mg 3 MK0633 MK0633 100 mg
- Primary Outcome Measures
Name Time Method Pulmonary function test data measured over 6 weeks 6 weeks
- Secondary Outcome Measures
Name Time Method Overall daytime and nighttime symptoms score, beta-agonist use, asthma exacerbations, asthma-specific quality of life questionnaire score, measured over 6 weeks 6 weeks